Literature DB >> 11285475

Biological characterization of Trypanosoma cruzi strains.

R A Martínez-Díaz1, J A Escario, J J Nogal-Ruiz, A Gómez-Barrio.   

Abstract

Biological parameters of five Trypanosoma cruzi strains from different sources were determined in order to know the laboratory behaviour of natural populations. The parameters evaluated were growth kinetics of epimastigotes, differentiation into metacyclic forms, infectivity in mammalian cells grown in vitro and parasite susceptibility to nifurtimox, benznidazole and gentian violet. Differences in transformation to metacyclic, in the percentage of infected cells as well as in the number of amastigotes per cell were observed among the strains. Regarding to pharmacological assays, Y strain was the most sensitive to the three assayed compounds. These data demonstrate the heterogeneity of natural populations of T. cruzi, the only responsible of infection in humans.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11285475     DOI: 10.1590/s0074-02762001000100006

Source DB:  PubMed          Journal:  Mem Inst Oswaldo Cruz        ISSN: 0074-0276            Impact factor:   2.743


  16 in total

1.  Proinflammatory and cytotoxic effects of hexadecylphosphocholine (miltefosine) against drug-resistant strains of Trypanosoma cruzi.

Authors:  Victor B Saraiva; Daniel Gibaldi; José O Previato; Lucia Mendonça-Previato; Marcelo T Bozza; Célio G Freire-De-Lima; Norton Heise
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

2.  Stationary phase in Trypanosoma cruzi epimastigotes as a preadaptive stage for metacyclogenesis.

Authors:  Roberto Hernández; Ana María Cevallos; Tomás Nepomuceno-Mejía; Imelda López-Villaseñor
Journal:  Parasitol Res       Date:  2012-05-31       Impact factor: 2.289

Review 3.  Experimental models in Chagas disease: a review of the methodologies applied for screening compounds against Trypanosoma cruzi.

Authors:  Cristina Fonseca-Berzal; Vicente J Arán; José A Escario; Alicia Gómez-Barrio
Journal:  Parasitol Res       Date:  2018-09-19       Impact factor: 2.289

4.  In vitro and in vivo activity of lignan lactones derivatives against Trypanosoma cruzi.

Authors:  Juliana Saraiva; Celeste Vega; Mirian Rolon; Rosangela da Silva; Márcio Luis Andrade E Silva; Paulo Marcos Donate; Jairo Kenupp Bastos; Alícia Gomez-Barrio; Sérgio de Albuquerque
Journal:  Parasitol Res       Date:  2006-10-12       Impact factor: 2.289

5.  Hydroxymethylnitrofurazone treatment in indeterminate form of chronic Chagas disease: Reduced intensity of tissue parasitism and inflammation-A histopathological study.

Authors:  Cauê B Scarim; Cleverton R de Andrade; João A da Rosa; Jean L Dos Santos; Chung M Chin
Journal:  Int J Exp Pathol       Date:  2018-10-15       Impact factor: 1.925

6.  Further insights into biological evaluation of new anti-Trypanosoma cruzi 5-nitroindazoles.

Authors:  Cristina Fonseca-Berzal; José Antonio Escario; Vicente J Arán; Alicia Gómez-Barrio
Journal:  Parasitol Res       Date:  2014-01-17       Impact factor: 2.289

7.  In vitro and in vivo high-throughput assays for the testing of anti-Trypanosoma cruzi compounds.

Authors:  Adriana M C Canavaci; Juan M Bustamante; Angel M Padilla; Cecilia M Perez Brandan; Laura J Simpson; Dan Xu; Courtney L Boehlke; Rick L Tarleton
Journal:  PLoS Negl Trop Dis       Date:  2010-07-13

8.  Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease.

Authors:  Shilpi Khare; Xianzhong Liu; Monique Stinson; Ianne Rivera; Todd Groessl; Tove Tuntland; Vince Yeh; Ben Wen; Valentina Molteni; Richard Glynne; Frantisek Supek
Journal:  Antimicrob Agents Chemother       Date:  2015-08-03       Impact factor: 5.191

9.  Experimental chemotherapy against Trypanosoma cruzi infection using ruthenium nitric oxide donors.

Authors:  Jean Jerley N Silva; Wander R Pavanelli; José Clayston M Pereira; João S Silva; Douglas W Franco
Journal:  Antimicrob Agents Chemother       Date:  2009-07-06       Impact factor: 5.191

Review 10.  CYP51 as drug targets for fungi and protozoan parasites: past, present and future.

Authors:  Galina I Lepesheva; Laura Friggeri; Michael R Waterman
Journal:  Parasitology       Date:  2018-04-12       Impact factor: 3.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.